ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
경카테터 심장판막 치환술(THVR) 시장 규모는 2024년부터 2030년까지 예측 기간 동안 13.75%의 연평균 복합 성장률(CAGR)로 확대될 것으로 예상됩니다. 경 카테터 심장 판막 치환술 시장은 순환기 질환, 다양한 심장 판막 질환을 포함한 심혈관 질환의 유병률 증가, 규제 승인과 같은 제품 개발 활동 증가, 좌식 생활 습관, 생활 습관병 증가로 인해 2024년부터 2030년까지 예측 기간 동안 경 카테터 심장 판막 치환술 시장의 전반적인 성장을 가속화할 것으로 예상되는 최소 침습 수술에 대한 선호도 증가로 인해 빠르게 성장하고 있습니다.
영국심장재단(BHF)에 따르면, 2024년에는 라이프스타일의 변화, 고령화, 인구 증가로 인해 2022년에는 전 세계적으로 약 6억 4,000만 명이 심장 및 순환기 질환을 앓고 있는 것으로 보고되고 있습니다.
세계보건기구(WHO)의 2020년 데이터에 따르면, 석회 침착성 대동맥판막 협착증의 유병률은 전 세계적으로 900만 명에 달할 전망입니다. 이처럼 심혈관 질환 및 다양한 심장 판막 질환을 포함한 심혈관 질환의 유병률 증가는 경 카테터 심장 판막 치환술에 대한 수요를 증가시킬 것으로 예상됩니다.
또한, 최소침습적 수술에 대한 환자들의 선호도가 높아지는 것도 예측 기간 동안 시장 성장에 긍정적인 영향을 미칠 것으로 보입니다. 경 카테터 심장판막 치환술은 최소 침습적 접근 방식을 통해 기존 수술에 비해 회복 시간 단축, 수술 후 통증 감소, 입원 기간 단축, 상처 합병증 감소, 더 나은 상처 보철물 등의 이점을 제공합니다.
이 보고서는 세계의 경피적 심장판막 치환술(Transcatheter Heart Valve Replacement) 시장에 대해 조사했으며, 시장 개요와 함께 제품별, 용도별, 최종사용자별 동향, 경쟁 구도, 국가별 동향 등의 정보를 전해드립니다.
목차
제1장 경카테터 심장판막 치환술 시장 보고서 서론
제2장 경카테터 심장판막 치환술 시장 주요 요약
제3장 경쟁 구도
제4장 규제 분석
미국
유럽
일본
중국
제5장 경카테터 심장판막 치환술 시장의 주요 요인 분석
경카테터 심장판막 치환술 시장 성장 촉진요인
경카테터 심장판막 치환술 시장 성장 억제요인과 과제
경카테터 심장판막 치환술 시장 기회
제6장 경카테터 심장판막 치환술 시장 : Porter의 Five Forces 분석
제7장 경카테터 심장판막 치환술 시장 평가
제품별
용도별
최종사용자별
지역별
제8장 경카테터 심장판막 치환술 시장 기업과 제품 개요
Medtronic
Boston Scientific Corporation
Bracco SpA
Edward Lifesciences
Meril Lifesciences
JenaValve Technologies Inc.
Venus Medtech(Hangzhou) Inc.
Abbott
Bluesail Medical Co., Ltd.
Braile Biomedica
CryoLife, Inc.
SMT
Peijia Medical Limited
P+F Products + Features GmbH
Livanova Plc
제9장 KOL(Key Opinion Leader)의 견해
제10장 프로젝트 접근
제11장 DelveInsight에 대해
제12장 면책사항과 문의
LSH
영문 목차
영문목차
Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing prevalence of cardiovascular disorders and increasing product developmental activities worldwide
The transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030. The transcatheter heart valve replacement market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter heart valve replacement market during the forecast period from 2024 to 2030.
According to the British Heart Foundation (BHF), it was reported in 2024, that around 640 million people in 2022 were living with heart and circulatory diseases across the world owing to changing lifestyles, aging, and a growing population.
As per data from the World Health Organization (WHO) 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Thus, the increasing prevalence of cardiovascular diseases including circulatory diseases and various heart valve diseases will increase the demand for transcatheter heart valve replacement.
The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Transcatheter heart valve replacement offer advantages over conventional surgeries owing to their minimally invasive approach, such as shorter recovery time, less post-operational pain, less stay at the hospital, fewer wound complications, and better wound prosthesis.
Additionally, in February 2024, Edwards Lifesciences Corporation announced launch of the Sapien 3 Ultra Resilia valve in Europe.
Therefore, the factors stated above collectively will drive the overall transcatheter heart valve replacement market growth.
However, presence of alternative treatment in the market, stringent regulatory approval process, among others may prove to be challenging factors for transcatheter heart valve replacement market growth.
Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the transcatheter heart valve replacement market, the transcatheter aortic valve replacement (TAVR) category is expected to have a significant revenue share in the year 2023. This is due to the increasing cases of aortic stenosis disorder as TAVR is the first-line surgical procedure performed for aortic stenosis. Further, the availability of technologically advanced devices in the market, and rising device launches and approvals will also affect the market positively.
The primary feature of this technique is its minimally invasive nature, as it involves accessing the aorta through the femoral artery in the groin, which typically results in a smaller incision and less surgical trauma. This approach leads to significant benefits, including a shorter recovery time.
Additionally, advancements in imaging and device technology have improved the precision of valve placement during the procedure, leading to better overall results. The transfemoral approach is also beneficial for patients with favorable femoral artery anatomy, as it allows for straightforward access without the need for complex surgical interventions.
Therefore the widespread uses and various features of transcatheter aortic valve replacement enhance performance and usability, solidifying the significant impact on the growth of the overall transcatheter heart valve replacement market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall transcatheter heart valve replacement market:
Among all the regions, North America is expected to dominate the transcatheter heart valve replacement market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and their associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter heart valve replacement market in the North America region during the forecast period from 2024 to 2030.
Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.
According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart valve diseases, which is increasing significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart valve disease.
Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for transcatheter heart valve replacement.
Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for transcatheter heart valve replacement. For example, in September 2021, Abbott announced that the U.S Food and Drug Administration approved the company's Portico(TM) with FlexNav(TM) transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American transcatheter heart valve replacement market.
Some of the key market players operating in the transcatheter heart valve replacement market include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.
Recent Developmental Activities in the Transcatheter Heart Valve Replacement Market:
In August 2024, Boston Scientific Corporation announced that it secured CE mark for the ACURATE Prime(TM) Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology.
In January 2022, Medtronic announced that the National Medical Products Administration (NMPA) approved the CoreValve Evolut PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery.
Key Takeaways from the Transcatheter Heart Valve Replacement Market Report Study
Market size analysis for current transcatheter heart valve replacement market size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the transcatheter heart valve replacement market
Various opportunities available for the other competitors in the Transcatheter Heart Valve Replacement market space
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current transcatheter heart valve replacement market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for transcatheter heart valve replacement market growth in the coming future?
Target Audience who can be benefited from this Transcatheter Heart Valve Replacement Market Report Study
Transcatheter heart valve replacement-related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in transcatheter heart valve replacement
Various end-users who want to know more about the transcatheter heart valve replacement market and the latest technological developments in the transcatheter heart valve replacement market
Frequently Asked Questions for the Transcatheter Heart Valve Replacement Market:
1. What are transcatheter heart valve replacement?
The transcatheter heart valve replacement is a procedure with a less invasive approach that helps replace the heart valve with a prosthetic valve to treat severe aortic stenosis and mitral regurgitation. It is an effective alternative to cumbersome open heart surgery, especially for high-risk patients.
2. What is the market for transcatheter heart valve replacement?
The transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030.
3. What are the drivers for the transcatheter heart valve replacement market?
The transcatheter heart valve replacement market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter heart valve replacement market during the forecast period from 2024 to 2030.
4. Who are the key players operating in the transcatheter heart valve replacement market?
Some of the key market players operating in transcatheter heart valve replacement include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.
5. Which region has the highest share in the transcatheter heart valve replacement market?
Among all the regions, North America is expected to dominate the transcatheter heart valve replacement market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter heart valve replacement market in the North America region during the forecast period from 2024 to 2030.
